Voltage-gated sodium channels (VGSCs) in peripheral nociceptive sensory neurons are critical to transmit pain signals. BmK I purified from the venom of scorpion Buthus martensi Karsch (BmK) has been demonstrated to be the primary contributor of envenomation-associated pain. However, the role of distinct VGSCs such as Nav1.6 in the induction and maintenance of pain behaviors induced by BmK I was ambiguous. Herein, using molecular and behavioral approaches we investigated the mRNA and protein expression profiles of Nav1.6 in rat DRG after intraplantar injection of BmK I and tested the pain behaviors after knockdown of Nav1.6 in BmK I-treated rats. It was shown that during induction and maintenance of pain responses induced by BmK I, the expression of Nav1.6 in DRG was found to be significantly increased at both mRNA and protein levels. The percentage of co-localization of Nav1.6 and Isolectin B4, a molecular marker of small diameter non-peptidergic DRG neurons, was increased at the maintenance phase of pain responses. Furthermore, spontaneous pain and mechanical allodynia, but not thermal hyperalgesia induced by BmK I, were significantly alleviated after knockdown of Nav1.6. These data strongly suggest that Nav1.6 plays an indispensable role in the peripheral pain hypersensitivity induced by BmK I.
Introduction
Sensory nociceptive neurons located in the dorsal root ganglia (DRG) play a pivotal role in the transmission of pain signals. Many sensitive receptors and ion channels were detected in DRG neurons. Potential or actual tissue-damaging stimuli, thermal and mechanical or chemical signals were transmitted from DRG neurons to the spinal cord dorsal horn [1, 2] .
A variety of sodium channel subtypes involved in pain signals generation and conduction were investigated in DRG neurons of different pain models, including TTX-sensitive (Nav1.1, Nav1.2, Nav1.3, Nav1.6, and Nav1.7) and TTX-resistant types (Nav1.8 and Nav1.9) [3, 4] . It is well known that Nav1.6 is the predominant sodium channel located in axon initial segments (AIS) and mature nodes of Ranvier in myelinated fibers [4] . Nav1.6-mediated persistent and resurgent currents in myelinated sensory could enhance cooling neuropathic pain responses induced by the chemotherapy drug oxaliplatin [5] . In a rat model of infraorbital nerve injury, the expression level of Nav1.6 was increased proximal to the lesion location [6] . Knockdown of Nav1.6 could relieve mechanical pain behavior in local inflammation and neuropathic pain models [7, 8] .
BmK I, a polypeptide consisting of 64 amino acid residues purified from the scorpion Buthus martensi Karsch (BmK) venom, can mimic BmK venom-induced spontaneous nociceptive response [9, 10] . It has been demonstrated that BmK I could increase peak sodium currents and inhibit the inactivation of both TTX-S and TTX-R channels on small DRG neurons in rats [11] [12] [13] . Peripheral administration of BmK І could up-regulate the mRNA and protein expression levels as well as the current density of Nav1.8 in DRG neurons. Knockdown of the Nav1.8 could attenuate the spontaneous flinching behavior and mechanical allodynia [14] . Transient and persistent currents of Nav1.6 expressed in Xenopus oocytes were increased during BmK I incubation (EC 50 value of BmK I for Nav1.6 = 214 ± 30 nM) [15] [16] [17] [18] .
The data mentioned above strongly hint that Nav1.6 may be involved in hyperalgesia induced by BmK I. As for it, the aim of the present study is to learn how Nav1.6 is evolved during induction and maintenance phases of the pain responses induced by BmK I.
Materials and Methods

Experimental animals
Adult male Sprague-Dawley rats (180-220 g) purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences (Shanghai, China) were fed in animal house at 21°C-23°C, 12-h light-dark cycle, water and food available ad libitum. All experiments were performed to comply with guidelines of International Association for the Study of Pain (IASP) [19] .
Drug preparation and administration
BmK I was purified from BmK venom according to the previously described procedures [9] , and the BmK venom was purchased from an individual scorpion culture farm in Zhengzhou, Henan Province of China. Then 10 μg of BmK I was dissolved in 50 μl of sterile saline, and injected into the left hind paw of rats. Pain-related behaviors were observed and evaluated ( Supplementary Fig. S1 ).
Intrathecal delivery of lentivirus
A sequence-specific guide RNA targeting the gene encoding Nav1.6 was designed and cloned into the lentiCRISPR-eGFP plasmid to knockdown Nav1.6. Adenoviral, adeno-associated viral (AAV) and lentiviral vectors have been applied for the delivery of CRISPR/Cas9 system in vivo [20] [21] [22] [23] . In this study, lentiviral vectors were used to deliver the CRISPR/Cas9 system into DRG neurons. The Nav1.6 gRNA lentivirus (Lv-CRISPR-eGFP-Scn8a-gRNA) and non-targeting lentivirus (Lv-CRISPR-eGFP) were produced and purified by Shanghai MixBioscience Co., Ltd (Shanghai, China). Sequences for gRNAs targeting Nav1.6 gene were as follows: gRNA1: 5′-CAAA GGCGGATGGCAGCCAC-3′; gRNA2: 5′-CAAGCCAAACAGTGA CCTGG-3′. Rats were randomly divided into 4 groups (n = 8 for each group): vehicle (saline), GFP (Lv-CRISPR-eGFP), gRNA1 (Lv-CRISPR-eGFP-Scn8a-gRNA1), and gRNA2 (Lv-CRISPR-eGFP-S cn8a-gRNA2) groups. Lentiviral vector (2.1 × 10 6 TU) or sterile saline (30 μl) was intrathecally injected into the intraspinal space between the L4 and L5 in rats 8 days before intraplantar administration of 50 μl diluted BmK I solution (0.2 μg/μl).
Transduction of BV2 cells with lentivirus
BV2 cells were cultured in the Dulbecco's modified Eagle's medium (Gibco Invitrogen, Carlsbad, USA) with 10% fetal bovine serum (Gibco Invitrogen) on a 6-well plate, maintained in a temperature (37°C) and CO 2 (5%) controlled humidified atmosphere as described previously [24, 25] . The procedure of the BV2 cell transduction with lentivirus (MOI = 20) was as follows: the cells were divided into four groups, which were respectively infected with no virus (BV2 cells only), Lv-CRISPR-eGFP, Lv-CRISPR-eGFP-Scn8a-gRNA1, and Lv-CRISPR-eGFP-Scn8a-gRNA2; second, the cell culture medium was replaced by the fresh medium 24 h post-transduction; third, after 3 days cultured, cells were harvested in lysis buffer containing protease inhibitors. 
RNA isolation and quantitative real-time RT-PCR
L4-L5 DRGs were rapidly harvested from rats at 1 h, 2 h, 4 h, 8 h, and 1 day (n = 3 for each time course) after intraplantar injection of 50 μl diluted BmK I solution (0.2 μg/μl). Total RNA was extracted with Total RNA extraction reagent (TaKaRa, Dalian, China). Then reverse transcription was performed with ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo, Osaka, Japan) according to the manufacturer's protocol. The PCR primers were as follows: Nav1.6-S: 5′-TCAAGTGCTGCCAGGTCAACA-3′; Nav1.6-A: 5′-AGGATGGTGCGGATCCTCTTC-3′; β-actin-S: 5′-AGCACTG TGTTGGCATAGAGGTC-3′; β-actin-A: 5′-ACTATCGGCAATGAG CGGTTCC-3′. All primers were designed by Primer Premier 6.0 software and synthesized by Genscript (Nanjing, China). Quantitative real-time RT-PCR was performed in the instrument with CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, USA) and THUNDERBIRD SYBR ® qPCR Mix (Toyobo, Osaka, Japan).
Amplification protocol included a pre-degeneration at 95°C for 20-60 s, followed by 45 cycles of 10 s at 95°C for denaturation and 45 s at 60°C for annealing and extension. Each sample was repeated with three replications. Data obtained were analyzed by ΔΔCt method.
Immunohistochemistry
After intraplantar injection of BmK I at different time points (2 h, 4 h, 8 h, and 1 day), rats were anesthetized and perfused with 200 ml of sterile saline, followed by 400 ml of fixative containing 4% paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.4). Bilateral L4-L5 DRGs were harvested, in 0.1 M PB containing 20% sucrose for dehydration until precipitates, then DRG tissues were moved into 0.1 M PB containing 30% sucrose till subsided again. Frozen sections at 14 μm were cut with Cryostat Microtome (HM 525; Thermo Fisher Microm, Walldorf, Germany). Frozen sections were incubated for 2 h with 5% horse serum in 0.01 M PBS to block non-specific binding sites, then sections were incubated with primary antibodies overnight at 4°C. Then, DRG sections were rinsed with 0.01 M PBS and incubated for 2 h with secondary antibodies at room temperature. After rinse again with 0.01 M PBS, coverslips were applied. Confocal images were obtained using a laser scan confocal fluorescent microscope (LSM710; Carl Zeiss, Jena, Germany). The primary antibodies were as follows: rabbit polyclonal to Nav1. 
Statistical analysis
All data were presented as the mean ± SEM and analyzed with Origin 8.5 software. The differences between groups were compared using Student's t-test or ANOVA followed by Fisher's PLSD post hoc analysis. P < 0.05 was considered statistically significant.
Results
Expression levels of Nav1.6 were increased in L4-L5 DRG neurons of BmK I-induced rat pain model
Real-time PCR experiment demonstrated that there was significant increase in the normalized Nav1.6 mRNA level at 4 h (from 100.00% ± 3.72% to 130.55% ± 7.50%, n = 3, P < 0.05), 8 h (from 100.00% ± 3.72% to 172.95% ± 2.80%, n = 3, P < 0.01), and 1 day (from 100.00% ± 3.72% to 138.90% ± 2.60%, n = 3, P < 0.05) in ipsilateral (left) L4-L5 DRG neurons after BmK I injection (Fig. 1A) . In contrast, Nav1.6 mRNA level was significantly decreased at 1 h (from 100.00% ± 13.23% to 66.40% ± 2.89%, n = 3, P < 0.05), and 2 h (from 100.00% ± 13.23% to 58.41% ± 2.59%, n = 3, P < 0.01) in contralateral (right) L4-L5 (Fig. 1B ). Nav1.6 protein level was changed at numerous special time points of 2 h, 8 h, 1 day after BmK I injection. It was shown that Nav1.6 protein levels of ipsilateral (left) DRG neurons were significantly increased from 100.00% ± 4.32% to 132.35% ± 5.56%, 170.83% ± 11.88% and 153.48% ± 5.93% in 2 h, 8 h, and 1 day groups, respectively ( Fig. 1C,E ). Nav1.6 protein levels were significantly increased from 100.00% ± 7.01% to 125.26% ± 1.60% at 2 h group in contralateral (right) L4-L5 DRG neurons (Fig. 1D,F) .
Schedule-related distribution of Nav1.6 co-localization with three neuron markers in bilateral L4-L5 DRG neurons
Immunohistochemistry experiment revealed the distribution of Nav1.6 in different DRG neurons at 2 h, 4 h, 8 h, and 1 day after BmK I injection (Figs. 2 and 3) . In ipsilateral (left) DRG neurons, percentages of co-localization of Nav1.6 and NF-200 decreased from 48.09% ± 1.93% to 37.37% ± 1.88% at 8 h (Fig. 2J ), Nav1.6 and IB4 increased from 37.24% ± 1.36% to 51.13% ± 1.46% at 1 day (Fig. 2K ), Nav1.6 and CGRP decreased from 37.42% ± 0.97% to 29.42% ± 0.33% at 2 h (Fig. 2L) . In contralateral (right) DRG neurons, the percentage of Nav1.6-positive neurons expressing NF-200 decreased from 47.68% ± 2.16% to 37.45% ± 1.47% at 8 h (Fig. 3J ), Nav1.6-positive neurons expressing IB4 increased from 36.45% ± 1.34% to 47.91% ± 1.43% at 1 day time point (Fig. 3K ), Nav1.6-positive neurons expressing CGRP decreased from 37.33% ± 1.09% to 26.87% ± 0.73% at 8 h (Fig. 3L) .
Effect of Nav1.6 gRNA lentiviral vector on Nav1.6 expression level in BV2 cells
The performance of Nav1.6 gRNA lentiviral vector was tested in BV2 cells before it was delivered into rats. Preliminary experiments applying moderate viral dose (MOI = 20) onto BV2 cells resulted in high EGFP fluorescent intensity, as shown in Fig. 4A -D. After 3 days of infection, Nav1.6 protein expression in BV2 cells was tested. Compared with control group, Nav1.6 protein levels of Lv-CRISPReGFP-Scn8a-gRNA1 and Lv-CRISPR-eGFP-Scn8a-gRNA2 groups were significantly decreased, while there was no obvious difference at Nav1.6 protein expression level of the Lv-CRISPR-eGFP group (Fig. 4E) .
Upregulation of Nav1.6 and pain responses induced by BmK I were suppressed by intrathecal injection of Nav1.6 gRNA lentiviral vector Nav1.6 gRNA lentiviral vector, non-targeted lentiviral vector (2.1 × 10 6 TU of purified vector) or vehicle was injected 8 days prior to BmK I administration. Ipsilateral (left) DRG tissues were harvested at 8 h after BmK I administration. GFP fluorescence was observed in DRG neurons transfected with Lv-CRISPR-eGFP, Lv-CRISPReGFP-Scn8a-gRNA1, and Lv-CRISPR-eGFP-Scn8a-gRNA2, but not in the vehicle group (Fig. 5A-D) . Compared with vehicle group, there was no discernible difference in Nav1.6 protein level of the Lv-CRISPR-eGFP group. Nevertheless, ipsilateral Nav1.6 protein levels of gRNA1 and gRNA2 group were significantly decreased (from 100.00% ± 2.25% to 58.38% ± 0.93%, 76.16% ± 3.27%, n = 6, P < 0.01, P < 0.05) as shown in Fig. 5E .
Then, the effects of Nav1.6 knockdown in L4-L5 DRGs on ipsilateral (left) pain responses induced by BmK I were tested. Likewise, Nav1.6 gRNA lentiviral vectors, non-targeted lentiviral vectors and vehicle were injected, respectively, 8 days prior to BmK I administration. It was shown that the ipsilateral spontaneous flinching behavior was suppressed by intrathecal injection of Nav1.6 gRNA lentiviral vector (F (3,23) = 34.41, P < 0.01) (Fig. 6A) . Mechanical hyperalgesia was restrained at 2 h (F (3,71) = 20.27, P < 0.01), 8 h (F (3,71) = 8.66, P < 0.05), 1 day (F (3,71) = 4.05, P < 0.01) by Lv-CRISPR-eGFP-Scn8a-gRNA1, at 2 h by Lv-CRISPR-eGFPScn8a-gRNA2 (F (3,71) = 20.27, P < 0.01) (Fig. 6B) . The injection of Lv-CRISPR-eGFP did not affect spontaneous flinching behavior and ipsilateral mechanical hyperalgesia compared with vehicle group, as shown in Fig. 6A ,B. Thermal hypersensitivity was not significantly affected by Nav1.6 gRNA lentiviral vector and nontargeted lentiviral vector compared with vehicle group at 2 h (F (3,71) = 1.05, P > 0.05), 4 h (F (3,71) = 1.39, P > 0.05), 8 h (F (3,71) = 1.97, P > 0.05), and 1 day (F (3,71) = 0.81, P > 0.05) (Fig. 6C) .
Discussion
Peripheral sensory neurons located in DRG and the trigeminal ganglia, constituting the first link in the chain of neurons making up somatosensory pathways. Normally, DRG neurons are relatively quiescent, can be hyperexcitable after some injuries, responding to noxious stimuli and converting them into electrical activities via the activation of voltage-gated sodium channels. It seems to be clear that hyperexcitability of injured DRG neurons involves the deployment of distinct sodium channels [27] [28] [29] .
Intraplantar injection of BmK I could induce paw edema in a dose-dependent manner in addition to other pain-related behaviors [15] . In this study, after BmK I injection, spontaneous pain behavior, bilateral mechanical pain sensitivity and unilateral thermal pain sensitivity emerged (Supplementary Fig. S1 ). Compared to other inflammatory models such as CFA (complete Freund's adjuvant) model, the development time course of BmK I-induced spontaneous pain responses could persist for more than 2 h in addition to the unique paroxysmal pain-like behavior. It should be noted that BmK I could markedly inhibit the inactivation of sodium currents, increase the peak sodium currents in acute isolated rat small primary afferent neurons and result in the hyperexcitability of neurons [17] . Besides, it could directly activate Nav1.8 and increase the expression level of Nav1.8 channel in ipsilateral DRG, A-803,467 (a selective Nav1.8 blocker) could reduce the spontaneous flinching behavior and mechanical hypersensitivity in BmK I-injected rats [14, 30] . Co-administration with bupivacaine, a non-specific sodium channels blocker, could abolish BmK I-induced spontaneous behaviors [15] . It thus indicated that Figure 1 . Expression of Nav1.6 in L4-L5 DRG after administration of BmK I in rats (A) Expression of Nav1.6 at mRNA level in ipsilateral L4-L5 DRG. (B) Expression of Nav1.6 at mRNA level in contralateral L4-L5 DRG. Changes of mRNA expression were normalized by β-actin. **P < 0.01 and *P < 0.05 compared with control group (n = 3), error bars indicate SEM. (C,D) Western blot analysis of Nav1.6 protein in DRG. Optical band density analysis revealed Nav1.6 protein level increased significantly in ipsilateral L4-L5 DRG (E) and contralateral L4-L5 DRG (F) after BmK I injection. ***P < 0.001, **P < 0.01, and *P < 0.05 compared with control group (n = 8), error bars indicate SEM.
BmK I-induced immediate nociceptive responses were mainly attributed to the quick activation of sodium channels on primary afferent neurons, and BmK I-induced pain model was distinct from other inflammatory pain models.
Previous studies using spinal nerve ligation and spared nerve injury pain models suggest that nerve injury decreases Nav1.6 mRNA expression in the injured L5 DRG, but the expression level of Nav1.6 protein was significantly increased proximal to the lesion site in a rat model of infraorbital nerve injury [6, 31] . The mRNA and protein levels of Nav1.6 were unchanged in inflammatory carrageenan-induced pain model [32] . It thus suggests that the abundance of Nav1.6 expression is dynamic in different pain models. Interestingly, the expression level of Nav1.6 mRNA and protein were both up-regulated significantly in ipsilateral L4-L5 DRG, but not in contralateral L4-L5 DRG at 2 h in the presence of BmK I. The underlying mechanism remains unclear. Down-regulation of Nav1.6 mRNA might be due to time-delayed transcription activity.
It seems that some pain models depend on small diameter peptidergic neurons alone [33, 34] , while others concentrate on both large diameter neurons and small diameter peptidergic neurons [3, 35, 36] , and Nav1.6 could be detectable in DRG neurons with various diameter [3] . In the present study, we found that Nav1.6 was predominantly expressed in large myelinated A-fiber neurons at the initial stage of pain-related responses. Co-localization percentages of Nav1.6 with large myelinated A-fiber neurons and Nav1.6 with small diameter peptidergic neurons were both decreased at different time pionts, but the expression level of Nav1.6 in small diameter non-peptidergic neurons was up-regulated at the maintenance phase of pain responses, suggesting that Nav1.6 expressed in small diameter non-peptidergic neurons may contribute to the maintenance of pain responses induced by BmK I.
It has been demonstrated that the loss-of-function mutations in Nav1.6 result in motor disorders, preventing assessment of painrelated behaviors in mature animals [37] . There are many applications of the CRISPR tools for genome modification in vivo/vitro [38] [39] [40] [41] [42] [43] [44] . Certainly, using Lv-CRISPR-GFP-Scn8a-gRNA to locally knockdown Nav1.6 in L4-L5 DRG is a feasible method in this study. It was found that the expression level of Nav1.6 and related pain behaviors in GFP group was of no significant difference compared with vehicle group, indicating that Lv-CRISPR-GFP-Scn8a-gRNA binds to Figure 3 . Co-localization of Nav1.6 with three neuron markers in contralateral (right) L4-L5 DRG neurons Nav1.6 was red and co-markers were green for all panels, while co-labeling revealed yellow. (A-C) Immunofluorescent histochemistry image stained with Nav1.6. (D-F) Immunofluorescent histochemistry image stained with NF200, IB4, CGRP, respectively. (G-I) This pattern is consistent with Nav1.6 and NF200, IB4, CGRP, respectively (J-L). Quantitative analysis of the number of co-localization neurons in total Nav1.6 positive cells. **P < 0.01 and *P < 0.05 compared with control group (n = 4), error bars indicate SEM.
Nav1.6 gene in DRG specifically. The ipsilateral spontaneous hyperalgesia and mechanical hyperalgesia, but not thermal hyperalgesia induced by BmK I could be relieved after knockdown of Nav1.6. It thus potentially indicates that Nav1.6 contributes to the generation and maintenance phases of spontaneous neociception and mechanical allodynia, but not thermal hyperalgesia in BmK I-induced pain.
In addition, the baseline of mechanical pain behaviors was constant after knockdown. It was consistent with earlier study that local knockdown of Nav1.6 in DRG did not alter the cutaneous sensitivity to mechanical stimulation in normal animals [8] . On the other hand, the von Frey method used in the study might be not suitable for measuring mechanical threshold as most animals already reach the cutoff value. Intrathecal injection is regarded as a method for DRG treatment with no sign of motor impairment [45] . Despite of some limitations such as leakage of injected solution into spinal cord, intrathecal injection is still a harmless and effective method compared with other methods [46, 47] .
In summary, the results made in the study provide solid evidence that Nav1.6 play an indispensable role in the peripheral pain hypersensitivity induced by BmK I.
Supplementary Data
Supplementary data is available at Acta Biochimica et Biophysica Sinica online. Figure 4 . Expression of Nav1.6 channel in BV2 cell line (A-D) The BV2 cell line was infected with the Lv-CRISPR-eGFP, Lv-CRISPR-eGFP-Scn8a-gRNA1, Lv-CRISPR-eGFP-Scn8a-gRNA2 at MOI of 20. After 3 days, the GFP fluorescence was noted in cells infected with the Lv-CRISPR-eGFP (B) or the Lv-CRISPR-eGFPScn8a-gRNA1 (C), and Lv-CRISPR-eGFP-Scn8a-gRNA2 (D), but not in the control group (A). (E) Western blotting results and densitometric analysis showed that the expression levels of Nav1.6 channel were significantly reduced in Lv-CRISPR-eGFP-Scn8a-gRNA1, and Lv-CRISPR-eGFP-Scn8a-gRNA2 groups at MOI of 20. While there was no obvious difference in Lv-CRISPR-eGFP group with control group in BV2 cell line. ***P < 0.001 and **P < 0.01 compared with control group (n = 3), error bars indicate SEM. Figure 5 . Expression of Nav1.6 in L4-L5 DRG after lentivectors injection Rats were pre-treated with Nav1.6 gRNA lentiviral vector 8 days before BmK I administration. Ipsilateral DRG tissues were harvested at 8 h after BmK I administration, the GFP fluorescence was noted in the DRG transfected with the Lv-CRISPR-eGFP (B), the Lv-CRISPR-eGFP-Scn8a-gRNA1 (C), and Lv-CRISPR-eGFP-Scn8a-gRNA2 (D), but not in the vehicle group (A). (E) Western blotting results and densitometric analyses showed that the expression levels of Nav1.6 channel were significantly reduced in Lv-CRISPR-eGFP-Scn8a-gRNA1 and Lv-CRISPR-eGFP-Scn8a-gRNA2 groups compared with vehicle groups. ***P < 0.001 and *P < 0.05 compared with vehicle group (n = 6), error bars indicate SEM.
